AR and nonpapillary renal cell carcinoma: Importantly, our findings that AR could enhance HIF2α and VEGF-A signaling, and anti-AR therapy with ASC-J9 suppressed ccRCC progression40, suggest that anti-AR therapy may represent a potential novel therapy to overcome the Sunitinib resistance to suppress ccRCC progression.